The DHA-to-EPA Ratio in Children's Omega-3 Supplements — and Why Most Products Get It Wrong

Walk down the supplement aisle and you'll see fish oil bottles marketed specifically for kids, splashed with cartoons and claims about brain health. Most list a total omega-3 count in bold. Fewer tell you how much of that is DHA versus EPA — and almost none explain why the ratio between those two fatty acids matters enormously for a developing nervous system. That gap between marketing and biology is exactly what this article is about.

DHA and EPA Are Not Interchangeable

Both are long-chain omega-3 polyunsaturated fatty acids, but they do different things in the body. DHA (docosahexaenoic acid) is the dominant structural fat in the brain and retina. It is embedded in neuronal cell membranes and is critical for the membrane fluidity that makes signal transmission possible (Campisi et al., Cochrane Database of Systematic Reviews, 2024). EPA (eicosapentaenoic acid) works more as a signaling molecule — modulating inflammation, influencing neurotransmitter pathways, and playing a meaningful role in mood regulation (Agostoni et al., International Journal of Molecular Sciences, 2017).

Here's where it gets biochemically interesting: these two fatty acids are not metabolically isolated from each other. Research by Brenna and colleagues demonstrated that dietary DHA can be retroconverted back to EPA in the body, meaning a high-DHA supplement can actually help maintain EPA status — what the authors describe as DHA "sparing" endogenous EPA (Brenna et al., The American Journal of Clinical Nutrition, 2019). The reverse pathway is far less efficient. So a child getting mostly EPA from a supplement is not automatically getting adequate DHA.

What Children's Brains Actually Demand

The brain undergoes its most rapid period of DHA accumulation during fetal development and the first years of life, but the need for DHA doesn't simply switch off at toddlerhood. Adequate omega-3 intake — with DHA as the key structural component — continues to support neurological development, membrane integrity, and anti-inflammatory function throughout childhood (Innis et al., Military Medicine, 2014).

For context on how seriously health bodies take DHA specifically: clinical guidelines for pregnant women recommend an additional 100–200 mg/day of DHA beyond baseline omega-3 intake, with higher amounts (600–1000 mg/day of DHA+EPA, or DHA alone) for women at risk of preterm birth — reflecting how central DHA is to early neurodevelopment (Cetin et al., American Journal of Obstetrics & Gynecology MFM, 2024). The emphasis on DHA specifically — not simply total omega-3 — is deliberate and evidence-based.

International intake recommendations across healthy populations reinforce that DHA and EPA should be considered separately rather than lumped together, and that DHA carries particular relevance for neurological outcomes (Calder et al., Nutrition Research Reviews, 2025).

The Depression Research Complicates the Picture — Usefully

Here's where the science becomes genuinely nuanced, and where the ratio question gets its sharpest edge. A 2024 Cochrane review of omega-3 supplementation for depression in children and adolescents found that EPA/DHA ratio, varied dosages, and treatment duration are all identified as factors that need rigorous study — because the current evidence can't yet tell us which formulations work best (Campisi et al., Cochrane Database of Systematic Reviews, 2024). A 2025 randomized clinical trial in JAMA Network Open specifically examined omega-3 fatty acids in pediatric major depressive disorder, further underscoring that this is an active area of clinical investigation rather than settled science (Berger et al., JAMA Network Open, 2026).

In adult depression research, EPA-predominant formulations have been found more effective than DHA-predominant ones — leading many manufacturers to produce high-EPA products. But children are not small adults. Their brains are still building structural architecture. Applying an adult EPA-heavy ratio to a supplement marketed for a six-year-old's brain development is not automatically appropriate, and the evidence to justify it in children simply doesn't yet exist at the level of certainty needed.

Where Most Products Go Wrong

The most common failure isn't a single ingredient — it's a ratio mismatch combined with a lack of transparency. A typical children's fish oil might deliver 180 mg EPA and 120 mg DHA per serving (a 3:2 EPA-to-DHA ratio), which echoes the standard ratio found in pharmaceutical-grade fish concentrate. That ratio was not developed with a child's structural brain needs in mind.

The broader problem: omega-3 intake recommendations specify amounts of individual fatty acids, yet most supplement labels only advertise total omega-3 content (Calder et al., Nutrition Research Reviews, 2025). A bottle claiming "500 mg omega-3" could contain mostly EPA, mostly DHA, or a significant amount of shorter-chain ALA that does not convert efficiently to either. Without breaking down the individual fatty acids, the label is telling you very little.

What to Actually Look for on the Label

This doesn't have to be complicated. Here's what matters when choosing a children's omega-3 supplement:

Find the DHA and EPA amounts listed separately. If the label doesn't break these out, that's a red flag.
For younger children (under 5–6) focused on brain and eye development, look for DHA-dominant or DHA-equal formulations. The structural case for DHA in early neurodevelopment is well established (Innis et al., Military Medicine, 2014; Brenna et al., The American Journal of Clinical Nutrition, 2019).
Ignore total omega-3 as a primary metric. A product with 300 mg of DHA is more targeted than one with 500 mg of total omega-3 in an undisclosed ratio.
Look for third-party testing certification (e.g., IFOS, NSF). Oxidized fish oil is not only ineffective — it may be counterproductive.
Dose matters, not just ratio. Even a well-formulated product at a very low serving size may not reach amounts studied in clinical research.

One important caveat: the evidence base for specific ratios in children is still developing. Researchers themselves are calling for more studies with varied DHA-to-EPA ratios in pediatric populations (Campisi et al., Cochrane Database of Systematic Reviews, 2024). Recommendations here reflect the available biochemical and clinical evidence — not a final consensus.

Talk to your child's pediatrician or a registered dietitian before starting any supplement regimen, especially if your child has a diagnosed condition. The right product for a healthy five-year-old will look different from one appropriate for a teenager with mood symptoms. Getting the ratio question right is a good starting point — but it's one piece of a larger nutritional picture.

References

Cetin, I., et al. (2024). Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth. American Journal of Obstetrics & Gynecology MFM. https://pubmed.ncbi.nlm.nih.gov/38070679/
Campisi, S.C., et al. (2024). Omega-3 fatty acid supplementation for depression in children and adolescents. The Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/39564892/
Agostoni, C., et al. (2017). The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/29207548/
Brenna, J.T., et al. (2019). DHA retroconversion revisited: dietary DHA spares endogenous EPA. The American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/31250891/
Innis, S.M., et al. (2014). Omega-3 fatty acid biochemistry: perspectives from human nutrition. Military Medicine. https://pubmed.ncbi.nlm.nih.gov/25373090/
Calder, P.C., et al. (2025). An overview of national and international long chain omega-3 polyunsaturated fatty acid intake recommendations for healthy populations. Nutrition Research Reviews. https://pubmed.ncbi.nlm.nih.gov/41277237/
Berger, A., et al. (2026). ω-3 Fatty Acids in Pediatric Major Depressive Disorder: A Randomized Clinical Trial. JAMA Network Open. https://pubmed.ncbi.nlm.nih.gov/41481294/